The company targets positive net income in the second half of 2026 amid a multi-year turnaround strategy.
Rockwell Medical (RMTI) outlined a 2026 net sales outlook of $70M-$75M during its Q1 2026 earnings call, signaling progress in its turnaround efforts. CEO Mark Strobeck described the company as sustainably profitable and stable, with plans to achieve positive net income in the second half of 2026.
The guidance follows a period of restructuring, with management emphasizing execution on long-term growth initiatives. Prior quarters saw mixed financial performance, but the company now aims to solidify its recovery trajectory.
No immediate market reaction was detailed in the call, though the outlook reflects confidence in operational improvements and cost management.